Opthea Limited Sponsored ADR (OPTEY)
OTHER OTC:OPTEY
Top Page
Opthea Limited Sponsored ADR
(OTC:OPTEY)
Select Model
Select Model
Rating:42Neutral
Price Target:
$3.00
▲(14900.00% Upside)
Action:N/ADate:07/18/25
OPT's overall stock score of 42 reflects significant financial challenges as the primary drag, with deep losses, negative equity, and cash burn overshadowing any minor positives like slight free cash flow improvement. Technical indicators further weigh on the score with a bearish trend, while the negative P/E ratio offers no valuation support. Investors should approach with caution given the high risk profile.
Positive Factors
Innovative Product Pipeline
OPT-302 targets VEGF-C and VEGF-D, offering a novel approach to treating wet AMD and DME. This innovative pipeline positions Opthea to potentially capture significant market share in the eye disease treatment sector.
Negative Factors
High Leverage
High leverage and negative equity suggest potential solvency issues, limiting financial flexibility and increasing risk, which could hinder long-term operational stability and growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Innovative Product Pipeline
OPT-302 targets VEGF-C and VEGF-D, offering a novel approach to treating wet AMD and DME. This innovative pipeline positions Opthea to potentially capture significant market share in the eye disease treatment sector.
Read all positive factors
Opthea Limited Sponsored ADR (OPTEY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$522.88M
Dividend YieldN/A
Average Volume (3M)0.00
Price to Earnings (P/E)<0.1
Beta (1Y)-0.01
Revenue Growth-80.09%
EPS Growth60.14%
CountryUS
Employees33
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)1.46
Shares Outstanding170,997,270
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-2.00
Price to Sales (P/S)1215.83
P/FCF Ratio-0.94
Enterprise Value/Market Cap1.32
Enterprise Value/Revenue3.78K
Enterprise Value/Gross Profit-5.81K
Enterprise Value/Ebitda-2.41
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)$200.00K
Opthea Limited Sponsored ADR Business Overview & Revenue Model
Company Description
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endot...
How the Company Makes Money
Opthea Limited generates revenue primarily through the development and commercialization of its proprietary therapies. The company's revenue model includes potential income from licensing agreements, partnerships, and future sales of its therapies...
Opthea Limited Sponsored ADR Financial Statement Overview
Summary
Income Statement
10
Very Negative
Balance Sheet
5
Very Negative
Cash Flow
15
Very Negative
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Opthea Limited Sponsored ADR Technical Analysis
Negative
0.02
Price Trends
0.03
Negative
0.39
Negative
1.79
Negative
Market Momentum
>-0.01
Negative
43.95
Neutral
50.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OPTEY, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.03, and below the 200-day MA of 1.79, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 43.95 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OPTEY.
Opthea Limited Sponsored ADR Risk Analysis
Opthea Limited Sponsored ADR disclosed 72 risk factors in its most recent earnings report. Opthea Limited Sponsored ADR reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
If our information technology systems or data, or those of our third-parties, upon whom we rely, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations' reputational harm' loss of revenue or profits; loss of customers or sales; and other adverse consequences. Q2, 2023
2.
We are subject to stringent and evolving U.S. and foreign laws, regulations, rules, contractual obligations, policies and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation; fines and penalties; a disruption of our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences. Q2, 2023
3.
agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. Q2, 2023
Opthea Limited Sponsored ADR Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $745.68M | -8.29 | -41.94% | ― | 1255.21% | 74.58% | |
57 Neutral | $796.97M | -2.83 | -73.34% | ― | ― | 17.88% | |
55 Neutral | $1.32B | -39.78 | -23.29% | ― | ― | 79.27% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $569.55M | -2.11 | -73.00% | ― | -91.16% | -112.24% | |
45 Neutral | $462.45M | -3.83 | -103.12% | ― | 91.30% | 30.69% | |
42 Neutral | $522.88M | 0.02 | ― | ― | -80.09% | 60.14% |
* Healthcare Sector Average
OPTEY
Opthea Limited Sponsored ADR
0.02
-3.18
-99.41%
LXRX
Lexicon Pharmaceuticals
1.76
1.26
252.00%
PRTA
Prothena
10.58
0.89
9.18%
RGNX
RegenXBio
8.96
3.55
65.62%
CRVS
Corvus Pharmaceuticals
15.67
12.80
445.99%
SLDB
Solid Biosciences
8.10
5.43
203.37%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.